Last reviewed · How we verify

NCT03391362

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Active, enrolled NA Last updated 23 October 2024
What this trial tests

NA trial testing Stereotactic Radiation in Brain Metastases in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
23 February 2018
Primary endpoint
1 February 2025
1 February 2026

Quick facts

Lead sponsorDana-Farber Cancer Institute
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment100
Start date23 February 2018
Primary completion1 February 2025
Estimated completion1 February 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Brain Metastases or Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-10 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Epidemiology of brain metastases and leptomeningeal disease.
    Lamba N, Wen PY, Aizer AA. · · 2021 · cited 264× · PMID 33908612 · DOI 10.1093/neuonc/noab101
  2. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
    Aizer AA, Lamba N, Ahluwalia MS, Aldape K, et al · · 2022 · cited 116× · PMID 35762249 · DOI 10.1093/neuonc/noac118
  3. Current Management and Progress in Radiotherapy for Small Cell Lung Cancer.
    Tjong MC, Mak DY, Shahi J, Li GJ, et al · · 2020 · cited 23× · PMID 32760673 · DOI 10.3389/fonc.2020.01146
  4. Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
    Aizer AA, Tanguturi SK, Shi DD, Catalano PJ, et al · · 2025 · cited 11× · PMID 40644657 · DOI 10.1200/jco-25-00056
  5. Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches.
    Levis M, Gastino A, De Giorgi G, Mantovani C, et al · · 2023 · cited 11× · PMID 37760591 · DOI 10.3390/cancers15184622
  6. A multidisciplinary management algorithm for brain metastases.
    Ramos A, Giantini-Larsen A, Pannullo SC, Brandmaier A, et al · · 2022 · cited 11× · PMID 36532509 · DOI 10.1093/noajnl/vdac176
  7. Single isocenter stereotactic irradiation for multiple brain metastases: current situation and prospects.
    Uto M, Torizuka D, Mizowaki T. · · 2022 · cited 10× · PMID 36057071 · DOI 10.1007/s11604-022-01333-7
  8. GOECP/SEOR radiotherapy guidelines for small-cell lung cancer.
    Couñago F, de la Pinta C, Gonzalo S, Fernández C, et al · · 2021 · cited 8× · PMID 33767969 · DOI 10.5306/wjco.v12.i3.115

Verify or expand the search:

Other recruiting trials for Brain Metastases

Currently open trials in the same condition.

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03391362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing